Efficacy of adjuvant chemotherapy in stage II colon cancer patients with twelve or more lymph nodes retrieve

doi:10.4251/wjgo.v17.i9.108470

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-3)

Tables (1-3)

Sum=0

Sep 15, 2025 (publication date) through Sep 15, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Oncol. Sep 15, 2025; 17(9): 108470
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.108470

Table 1 The clinicopathological characteristics of the Surveillance, Epidemiology, and End Results cohort and the Chinese cohort, n (%)

Characteristics	SEER database	Chinese registry
Total	32742	3153
Examined lymph node, median (IQR)	20.00 (15.00, 26.00)	18.00 (15.00, 22.00)
Chemotherapy
No	28228 (86.2)	1429 (45.3)
Yes	4514 (13.8)	1724 (54.7)
Size, median (IQR)	5.00 (3.80, 7.00)	5.00 (4.00, 6.50)
Age
≥ 65	22829 (69.7)	1269 (40.2)
20-64	9913 (30.3)	1884 (59.8)
Sex
Female	17156 (52.4)	1345 (42.7)
Male	15586 (47.6)	1808 (57.3)
Grade
Grade 1/2	26221 (80.1)	2758 (87.5)
Grade 3/4	6521 (19.9)	395 (12.5)
Histology
Adenocarcinoma	27996 (85.5)	2683 (85.1)
Mucinous adenocarcinoma	4222 (12.9)	425 (13.5)
Others	524 (1.6)	45 (1.4)
T stage
T3	27920 (85.3)	2234(70.9)
T4	4822 (14.7)	919 (29.1)

SEER: Surveillance, Epidemiology, and End Results; IQR: Interquartile range.

Full Size Table

Table 2 Univariate and multivariate analysis of prognostic factors in the Surveillance, Epidemiology, and End Results cohort and the Chinese cohort

Characteristics	Univariate analysis¹		Multivariate analysis¹		Univariate analysis²		Multivariate analysis²
Characteristics	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value
ELN, median (IQR)	0.978 (0.976, 0.980)	< 0.001	0.984 (0.982, 0.986)	< 0.001	0.958 (0.940, 0.976)	< 0.001	0.962 (0.944, 0.979)	< 0.001
Size, median (IQR)	1.005 (1.000, 1.010)	0.03	1.004 (1.000, 1.009)	0.057	0.996 (0.946, 1.048)	0.87
Age
20-64	0.302 (0.286-0.318)	< 0.001	0.333 (0.315-0.351)	< 0.001	0.346 (0.275-0.437)	< 0.001	0.414 (0.326-0.526)	< 0.001
Sex
Male	1.039 (1.002-1.078)	0.039	1.160 (1.118-1.203)	< 0.001	1.196 (0.951-1.505)	0.126
Grade
Grade 3/4	1.214 (1.162-1.268)	< 0.001	1.154 (1.103-1.208)	< 0.001	1.212 (0.886-1.657)	0.23
Histology
Adenocarcinoma
Mucinous adenocarcinoma	1.045 (0.991-1.103)	0.104	1.011 (0.958-1.067)	0.695	1.086 (0.786-1.500)	0.616
Others	1.251 (1.088-1.440)	0.002	1.104 (0.956-1.274)	0.178	0.721 (0.269-1.936)	0.516
T stage
T4	1.568 (1.495-1.644)	< 0.001	1.795 (1.709-1.886)	< 0.001	1.497 (1.192-1.879)	0.001	1.569 (1.249-1.970)	< 0.001
Chemotherapy
Yes	1.885 (1.768-2.009)	< 0.001	1.589 (1.485-1.700)	< 0.001	2.246 (1.775-2.841)	< 0.001	1.865 (1.465-2.375)	< 0.001

¹Surveillance, Epidemiology, and End Results database.

²Chinese registry.

HR: Hazard ratio; CI: Confidence interval; ELN: Examined lymph node; IQR: Interquartile range.

Full Size Table

Table 3 The clinicopathological characteristics of the Surveillance, Epidemiology, and End Results and Chinese cohorts before and after propensity score matching, n (%)

Characteristics	Before PSM¹			After PSM¹			Before PSM²			After PSM²
Characteristics	No	Yes	P value	No	Yes	P value	No	Yes	P value	No	Yes	P value
Total	28228	4514		4204	4204		1429	1724		1163	1163
ELN, mean ± SD	22.18 ± 9.92	23.36 ± 10.69	< 0.001	22.52 ± 10.15	23.40 ± 10.72	< 0.001	19.98 ± 8.28	19.79 ± 7.59	0.502	19.68 ± 7.83	19.97 ± 7.64	0.368
Size, mean ± SD	5.55 ± 3.50	6.13 ± 3.66	< 0.001	6.08 ± 3.88	6.13 ± 3.52	0.568	5.21 ± 2.15	5.46 ± 2.23	0.002	5.23 ± 2.15	5.28 ± 2.08	0.58
Age			< 0.001			0.658			< 0.001			0.834
20-64	7144 (25.3)	2769 (61.3)		2438 (58.0)	2459 (58.5)		681 (47.7)	1203 (69.8)		666 (57.3)	660 (56.7)
Sex			< 0.001			0.169			0.097			0.474
Male	13274 (47.0)	2312 (51.2)		2128 (50.6)	2192 (52.1)		796 (55.7)	1012 (58.7)		673 (57.9)	691 (59.4)
Grade			< 0.001			0.96			1			0.9
Grade 3/4	5395 (19.1)	1126 (24.9)		1025 (24.4)	1028 (24.5)		179 (12.5)	216 (12.5)		145 (12.5)	142 (12.2)
Histology			0.255			0.436			0.002			0.164
Adenocarcinoma	24161 (85.6)	3835 (85.0)		3610 (85.9)	3591 (85.4)		1238 (86.6)	1445 (83.8)		1011 (86.9)	981 (84.4)
Mucinous adenocarcinoma	3627 (12.8)	595 (13.2)		531 (12.6)	535 (12.7)		164 (11.5)	261 (15.1)		138 (11.9)	169 (14.5)
Others	440 (1.6)	84 (1.9)		63 (1.5)	78 (1.9)		27 (1.9)	18 (1.0)		14 (1.2)	13 (1.1)
T stage			< 0.001			0.641			0.27			0.525
T4	3167 (11.2)	1655 (36.7)		1369 (32.6)	1348 (32.1)		402 (28.1)	517 (30.0)		336 (28.9)	351 (30.2)

¹Surveillance, Epidemiology, and End Results database.

²Chinese registry.

PSM: Propensity score matching; ELN: Examined lymph node.

Full Size Table

Citation: Huo Y, Zhang YY, Jiao S, Bai ZY, Bai WQ, Zhou HT, Guan X. Efficacy of adjuvant chemotherapy in stage II colon cancer patients with twelve or more lymph nodes retrieve. World J Gastrointest Oncol 2025; 17(9): 108470
URL: https://www.wjgnet.com/1948-5204/full/v17/i9/108470.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i9.108470